- Home
- FRHC vs LEGN Comparison
FRHC vs LEGN Comparison
Compare FRHC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRHC | LEGN |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 3.6B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FRHC | LEGN |
|---|---|---|
| Price | $173.41 | $19.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $46.90 |
| AVG Volume (30 Days) | 49.0K | ★ 1.7M |
| Earning Date | 11-06-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.29 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $2,191,291,000.00 | N/A |
| Revenue This Year | N/A | $39.04 |
| Revenue Next Year | N/A | $25.29 |
| P/E Ratio | $329.96 | ★ N/A |
| Revenue Growth | ★ 6.86 | N/A |
| 52 Week Low | $107.98 | $16.24 |
| 52 Week High | $178.00 | $37.50 |
Technical Indicators
Market Signals| Indicator | FRHC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 51.01 |
| Support Level | $145.61 | $17.81 |
| Resistance Level | $174.21 | $20.39 |
| Average True Range (ATR) | 4.91 | 0.77 |
| MACD | -0.39 | 0.25 |
| Stochastic Oscillator | 43.05 | 88.36 |
Price Performance
Historical ComparisonAbout FRHC Freedom Holding Corp.
Freedom Holding Corp is a holding company with reportable segments into the following four segments: Brokerage, Banking, Insurance, and Other. The majority of revenue is from the Banking segment. Banking segment consists of the operations of Freedom Bank KZ and Freedom Bank TJ. Geographically, operates in Kazakhstan, Armenia, Cyprus, the USA, and others, with maximum revenue from Kazakhstan.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.